239 related articles for article (PubMed ID: 16359177)
1. P450 2C18 catalyzes the metabolic bioactivation of phenytoin.
Kinobe RT; Parkinson OT; Mitchell DJ; Gillam EM
Chem Res Toxicol; 2005 Dec; 18(12):1868-75. PubMed ID: 16359177
[TBL] [Abstract][Full Text] [Related]
2. Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation.
Cuttle L; Munns AJ; Hogg NA; Scott JR; Hooper WD; Dickinson RG; Gillam EM
Drug Metab Dispos; 2000 Aug; 28(8):945-50. PubMed ID: 10901705
[TBL] [Abstract][Full Text] [Related]
3. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac.
Tang W; Stearns RA; Wang RW; Chiu SH; Baillie TA
Chem Res Toxicol; 1999 Feb; 12(2):192-9. PubMed ID: 10027798
[TBL] [Abstract][Full Text] [Related]
4. Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation.
Munns AJ; De Voss JJ; Hooper WD; Dickinson RG; Gillam EM
Chem Res Toxicol; 1997 Sep; 10(9):1049-58. PubMed ID: 9305589
[TBL] [Abstract][Full Text] [Related]
5. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac.
Shen S; Marchick MR; Davis MR; Doss GA; Pohl LR
Chem Res Toxicol; 1999 Feb; 12(2):214-22. PubMed ID: 10027801
[TBL] [Abstract][Full Text] [Related]
6. Decreases in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-treated rats.
Yamazaki H; Komatsu T; Takemoto K; Saeki M; Minami Y; Kawaguchi Y; Shimada N; Nakajima M; Yokoi T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):427-34. PubMed ID: 11259327
[TBL] [Abstract][Full Text] [Related]
7. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4.
Komatsu T; Yamazaki H; Asahi S; Gillam EM; Guengerich FP; Nakajima M; Yokoi T
Drug Metab Dispos; 2000 Nov; 28(11):1361-8. PubMed ID: 11038165
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.
Avent KM; DeVoss JJ; Gillam EM
Chem Res Toxicol; 2006 Jul; 19(7):914-20. PubMed ID: 16841959
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.
Minoletti C; Dijols S; Dansette PM; Mansuy D
Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023
[TBL] [Abstract][Full Text] [Related]
10. Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs.
Mancy A; Antignac M; Minoletti C; Dijols S; Mouries V; Duong NT; Battioni P; Dansette PM; Mansuy D
Biochemistry; 1999 Oct; 38(43):14264-70. PubMed ID: 10572000
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
Dehal SS; Kupfer D
Cancer Res; 1997 Aug; 57(16):3402-6. PubMed ID: 9270005
[TBL] [Abstract][Full Text] [Related]
12. Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9.
Jean P; Lopez-Garcia P; Dansette P; Mansuy D; Goldstein JL
Eur J Biochem; 1996 Nov; 241(3):797-804. PubMed ID: 8944768
[TBL] [Abstract][Full Text] [Related]
13. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.
Giancarlo GM; Venkatakrishnan K; Granda BW; von Moltke LL; Greenblatt DJ
Eur J Clin Pharmacol; 2001 Apr; 57(1):31-6. PubMed ID: 11372587
[TBL] [Abstract][Full Text] [Related]
14. The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9.
Rowland A; Elliot DJ; Knights KM; Mackenzie PI; Miners JO
Drug Metab Dispos; 2008 May; 36(5):870-7. PubMed ID: 18256202
[TBL] [Abstract][Full Text] [Related]
15. Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar.
Zhang D; Wang L; Chandrasena G; Ma L; Zhu M; Zhang H; Davis CD; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):139-49. PubMed ID: 17062778
[TBL] [Abstract][Full Text] [Related]
16. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways.
Picard N; Cresteil T; Djebli N; Marquet P
Drug Metab Dispos; 2005 May; 33(5):689-95. PubMed ID: 15743975
[TBL] [Abstract][Full Text] [Related]
17. Human cytochrome p450 enzymes of importance for the bioactivation of methyleugenol to the proximate carcinogen 1'-hydroxymethyleugenol.
Jeurissen SM; Bogaards JJ; Boersma MG; ter Horst JP; Awad HM; Fiamegos YC; van Beek TA; Alink GM; Sudhölter EJ; Cnubben NH; Rietjens IM
Chem Res Toxicol; 2006 Jan; 19(1):111-6. PubMed ID: 16411663
[TBL] [Abstract][Full Text] [Related]
18. Bioactivation of phencyclidine in rat and human liver microsomes and recombinant P450 2B enzymes: evidence for the formation of a novel quinone methide intermediate.
Driscoll JP; Kornecki K; Wolkowski JP; Chupak L; Kalgutkar AS; O'Donnell JP
Chem Res Toxicol; 2007 Oct; 20(10):1488-97. PubMed ID: 17892269
[TBL] [Abstract][Full Text] [Related]
19. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases.
Sridar C; Goosen TC; Kent UM; Williams JA; Hollenberg PF
Drug Metab Dispos; 2004 Jun; 32(6):587-94. PubMed ID: 15155549
[TBL] [Abstract][Full Text] [Related]
20. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
